DnB Asset Management AS Has $303,000 Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

DnB Asset Management AS increased its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 32.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 22,943 shares of the company’s stock after purchasing an additional 5,581 shares during the quarter. DnB Asset Management AS’s holdings in Syndax Pharmaceuticals were worth $303,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the company. State Street Corp lifted its holdings in shares of Syndax Pharmaceuticals by 4.1% during the 3rd quarter. State Street Corp now owns 3,770,826 shares of the company’s stock worth $72,588,000 after acquiring an additional 148,491 shares during the period. Assenagon Asset Management S.A. raised its position in Syndax Pharmaceuticals by 343.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 2,064,456 shares of the company’s stock valued at $27,292,000 after purchasing an additional 1,598,428 shares in the last quarter. Geode Capital Management LLC lifted its stake in Syndax Pharmaceuticals by 3.5% during the third quarter. Geode Capital Management LLC now owns 1,977,082 shares of the company’s stock worth $38,066,000 after purchasing an additional 66,459 shares during the last quarter. Franklin Resources Inc. boosted its holdings in shares of Syndax Pharmaceuticals by 13.4% in the 3rd quarter. Franklin Resources Inc. now owns 1,763,277 shares of the company’s stock valued at $34,948,000 after purchasing an additional 208,043 shares in the last quarter. Finally, Sphera Funds Management LTD. increased its stake in shares of Syndax Pharmaceuticals by 25.9% in the 3rd quarter. Sphera Funds Management LTD. now owns 1,034,846 shares of the company’s stock valued at $19,921,000 after purchasing an additional 212,799 shares during the last quarter.

Insider Transactions at Syndax Pharmaceuticals

In other news, insider Neil Gallagher sold 4,618 shares of Syndax Pharmaceuticals stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $71,579.00. Following the completion of the transaction, the insider now directly owns 85,095 shares of the company’s stock, valued at approximately $1,318,972.50. This trade represents a 5.15 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Michael A. Metzger sold 13,288 shares of the business’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $205,964.00. Following the completion of the transaction, the chief executive officer now directly owns 300,121 shares in the company, valued at $4,651,875.50. This represents a 4.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 21,683 shares of company stock worth $336,087. Company insiders own 4.10% of the company’s stock.

Syndax Pharmaceuticals Stock Up 8.0 %

Shares of NASDAQ:SNDX opened at $12.97 on Thursday. The firm has a market cap of $1.12 billion, a P/E ratio of -3.57 and a beta of 0.92. Syndax Pharmaceuticals, Inc. has a 12-month low of $11.63 and a 12-month high of $25.07. The business has a fifty day simple moving average of $14.23 and a 200 day simple moving average of $15.75.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.79). The firm had revenue of $7.68 million during the quarter, compared to the consensus estimate of $86.32 million. As a group, equities research analysts expect that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on SNDX. JPMorgan Chase & Co. upped their price objective on Syndax Pharmaceuticals from $39.00 to $41.00 and gave the stock an “overweight” rating in a research report on Thursday, March 20th. Citigroup reduced their price target on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating on the stock in a research note on Tuesday, March 4th. HC Wainwright reiterated a “buy” rating and set a $51.00 price objective on shares of Syndax Pharmaceuticals in a research report on Tuesday, March 4th. Scotiabank cut their target price on shares of Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating on the stock in a research report on Wednesday, January 8th. Finally, StockNews.com raised shares of Syndax Pharmaceuticals to a “sell” rating in a research note on Wednesday. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $36.20.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).